<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="69948">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02195180</url>
  </required_header>
  <id_info>
    <org_study_id>GRASPANC 2013-03</org_study_id>
    <secondary_id>2013-004262-34</secondary_id>
    <nct_id>NCT02195180</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma</brief_title>
  <official_title>Phase II, Randomized, Controlled, Clinical Trial Exploring Efficacy and Safety of ERY001 (L-asparaginase Encapsulated in Red Blood Cells) in Association With Gemcitabine or FOLFOX4 in Second-line Therapy for Patients With Progressive Metastatic Pancreatic Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ERYtech Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ERYtech Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A new approach that aims to destroy pancreatic tumor cells through modification of the tumor
      environment.

      Asparagine synthetase (ASNS) is an enzyme wich synthetise asparagine. Asparagine is an
      essential nutriment for pancreatic cancer cells which have no or low level of ASNS.

      by L-asparaginase encapsulated in erythrocytes deplete (supress) Plasma asparagine.

      in selected patients having no or low ASNS, may provide a new therapeutic approach.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 2014</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>week 16</time_frame>
    <description>Progression Free Survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency, severity and relationship to study treatments of adverse events</measure>
    <time_frame>every week 4 up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">141</enrollment>
  <condition>Pancreatic Adenocarcinoma Metastatic</condition>
  <arm_group>
    <arm_group_label>standard of care combined with ERY001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>standard of care = Gemcitabine or folfox</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard of care alone</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>standard of care = Gemcitabine or folfox</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ERY001</intervention_name>
    <arm_group_label>standard of care combined with ERY001</arm_group_label>
    <other_name>L asparaginase encapsulated in erythrocytes</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <arm_group_label>standard of care combined with ERY001</arm_group_label>
    <arm_group_label>standard of care alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluoro-uracil/oxaliplatin/leucovorin (folfox)</intervention_name>
    <description>oxaliplatin 85 mg/m2 levo-leucovorin 200 mg/m2 5-FU 400 mg/m2</description>
    <arm_group_label>standard of care combined with ERY001</arm_group_label>
    <arm_group_label>standard of care alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  progressive metastatic exocrine pancreatic adenocarcinoma

          -  Patients with available histology specimen, either from primary tumor and/or from
             metastatic lesions.

          -  eligible to 2nd line gemcitabine or FOLFOX4 treatment

          -  Measurable lesion (&gt;1cm) as assessed by CT scan or MRI (Magnetic Resonance Imaging)
             according to RECIST criteria (version 1.1)

          -  Patient aged 18 years and older

          -  ECOG (WHO) performance status 0-1

          -  Signed Informed Consent

        Exclusion Criteria:

          -  Patient who have received Oxaliplatine in first line will not be eligible in FOLFOX
             arm; Patient who received Gemcitabine in first line will not be eligible in
             Gemcitabine arm

          -  Patient with cerebral metastasis

          -  Patient with resectable or borderline non metastatic pancreatic adenocarcinoma

          -  Patient with known hypersensitivity to L-asparaginase or have had prior exposure to
             any form of L-asparaginase

          -  Anti-vitamin K treatment. Replacement with low molecular weight heparin treatment if
             required

          -  Patient unable to receive treatments based on gemcitabine or FOLFOX4 or ERY001, due
             to general or visceral conditions unrelated to pancreatic cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascal Hammel, Pr MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Beaujon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Beaujon</name>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>February 6, 2017</lastchanged_date>
  <firstreceived_date>July 16, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreas</keyword>
  <keyword>adenocarcinoma</keyword>
  <keyword>cancer</keyword>
  <keyword>asparaginase</keyword>
  <keyword>erythrocytes</keyword>
  <keyword>red blood cell</keyword>
  <keyword>Encapsulation</keyword>
  <keyword>folfox</keyword>
  <keyword>gemcitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
